All right, great. Thanks, everybody, for joining. My name is Ash Verma. I cover SMID Biotech and Spec Pharma at UBS, and very excited to have United Therapeutics. I have James Edgemond, who is the CFO, and Harry Silvers, who is the IR. Thank you guys so much for joining. Really excited to hear about the story. Maybe, I know a lot of people know your story very well, so you don't really need an introduction as such, but maybe James, if you can hit some highlights from the third quarter earnings that you recently released.
Yeah. Thank you, Ash. Thanks for hosting Harry and I and United Therapeutics here at your London Healthcare Conference. Harry's going to do a quick
Yeah
opening remark.
Yeah. Ash, thanks for having us. Thanks, everybody in the room and online. Just before James goes, quick disclaimer, we may make some forward-looking statements today, and for any risks and uncertainties associated with those statements, please refer to our filings on Forms 10-K and 10-Q.
Great. Thank you, Harry. Ash, back to your question. Across the board, we're incredibly proud of what all the Unitherians are performing across the organization. I think just a few highlights, just to break it down, from a commercial standpoint, the base business is performing extremely well. For the third quarter, we reported total revenues that were over $800 million, $833 million. A big part of that was the TYVASO franchise, which reported record revenue of $503 million, $504 million. From a commercial standpoint and base business standpoint, the teams are performing incredibly well, and we see a lot of opportunity for continued growth.
On the pipeline and the research and development side, as you know, there's a lot of activity that's happening just in terms of across-the-board clinical development to be able to find the right therapies and the right delivery devices to really serve and support the patients, and we're very proud to do that. As you know, looking ahead to 2027, there's some significant activity for us, including the FDA did accept our sNDA to use nebulized TYVASO in IPF, and the clinical trial results were really powerful and should have a clear benefit if approved for the patients. In addition, the NDA for ralinepag in PAH was accepted, and we have a PDUFA date mid-next year to serve and support those patients, which could potentially be the only once-a-day oral therapy for PAH.
We actually announced too that in the third and fourth quarter of 2027, our TETON clinical trial for PPF, so progressive pulmonary fibrosis, we're going to unblind as well. Really big events happening next year, a lot of clinical development as well. I think coming after that and thinking about the results we've had, we've made some great capital allocation decisions where we have a share repurchase going on right now. The board authorized us for another $2 billion, and we actually used some of our capital to buy down a royalty from Pfizer associated with ralinepag. It should demonstrate, and we had a lot of conviction in that business. Across the board, Ash, a lot of things going on, incredibly proud, and just setting up for Q4 and a 2027 very active year as well.
Wonderful. That's great. I think the third quarter revenue was a big positive surprise for us as well. I think just looking at TYVASO, I know there is a few different positives that have played out for you recently. I'm just trying to understand the step-up of growth that we saw in 3Q. Is there a particular driver? We had the sales force expansion recently in beginning of summer, I guess. Is that driving it, or is it coming from PAH, PH-ILD? Just help us understand what are the key drivers of this type of growth?
Yeah, it's a good question, and we've had that quite a bit. When we exited Q2, what Michael had talked about was the sales teams were seeing a lot of referrals and starts. The messaging was working, the base business was working, and you saw that pull through into Q3 revenue. You mentioned the sales force expansion. Kind of in the July, August timeframe, we talked about expanding the sales force ultimately to move into idiopathic pulmonary fibrosis if that sNDA is approved. But in the meantime, those sales teams have actually been engaged in both deepening the relationships with physicians, focusing on the messaging in terms of diagnosis, use of TYVASO in PAH and PH-ILD. And so those additional sales teams are actually helping us broaden that awareness of the disease state.
I think what you'll find is the core business is working well, that messaging was working, and you'll start to see the new sales team's impact more looking at Q4 and then looking into 2027. But it just goes to show you when Michael talked about looking at the messaging and really honing in on those relationships and talking about diagnosis really was working, and you saw that coming out of Q2 into Q3, and looking forward to that continuing going forward.
Yeah, I think it's fascinating to see that, especially I think that you made more of a commentary on coming out of Q2 that the referrals were at a record pace. Are you seeing that because of the sales force expansion that the referrals are getting a good boost going into Q4?
Yeah. It's a good question because if you refer back to what Michael talked about coming out of Q3, in the month of October, there was over 1,000 referrals across our commercial portfolio, which was the highest referrals in a single month ever. So with that momentum that you saw in Q3, coming out of Q2, you saw in Q3, October was a very large month for referrals. So that should give a good indication that this momentum is continuing and those sales teams are having an impact, and potentially a larger impact going forward.
Yeah. I think one of the questions that I always get from investors is that, is there any off-label IPF that is driving this? Just anything that you can say on that.
There certainly could be, but we certainly-
Yeah
don't market to it, and it would be hard for us to get visibility into that because it's not reimbursable specifically for IPF.
Right.
Could there be? Sure, because a physician can certainly write what they deem to be the best therapy for patients. But visibility-wise, we wouldn't necessarily get visibility on the reimbursement side.
Yeah. Okay, great. Just in terms of the growth opportunity, if we stick to the base business between PAH and PH-ILD, when you think about TYVASO, is that primarily coming from PH-ILD, or is PAH growing at all for TYVASO?
Yeah, absolutely. Look, going ahead from here, PH-ILD still remains highly under-penetrated and a really large opportunity for us, and one where we now have largely uncontested growth given some of the recent outcomes on the litigation side. PAH is still a grower. It is, albeit relatively modest when you think about PH-ILD. Both businesses are doing well, but you should really think about PH-ILD as a large growth driver on the legacy side.
Yeah. Got it. Okay. I think there has been a lot of focus on the PH-ILD growth, particularly after the settlement. It is interesting to hear your commentary at 3Q, because I think a lot of investors were maybe expecting that there would be some sort of transition that would happen from YUTREPIA to TYVASO, which I know you have sort of said that the expectation should be very moderate for that. But I want to talk about that a little bit, just maybe in terms of the existing patients and new patient dynamic. So, for the existing patient that might have been on YUTREPIA, at some point of time, these patients would require a prior authorization approval from the payers. Does that in any way trigger more of a transition for patients to come to TYVASO at that point?
Sure. I think you are thinking about reauthorizations when the calendar year turns. At some point, Liquidia has instructed the FDA that the label is going to be updated to remove PH-ILD. At some point when that happens, payers may update their coverage policies, and at that point in time is where you would really see the impact. But that is really going to vary payer by payer in terms of when or if that happens at all. Again, as I said before, a lot of the opportunity here is on the prior authorization side and new PH-ILD patients potentially coming in. We really contemplated this whole thing with the settlement in the damages structure, which half of the damages really contemplated potential continuing sales of YUTREPIA into PH-ILD patients, and we are getting paid for that already.
So again, when you think about the opportunity, it is going forward from here, again, largely uncontested space in PH-ILD.
Do you have a sense of how much six-month versus 12-month tie-out is in this market in general? Is that any way to get a good number on that?
No, not that I am aware of. No.
Got it. Okay. When we talk about the new patient dynamic on PH-ILD, so like you said, PH-ILD is growing for you already. It was surprising to see how much of growth the competitor had been benefiting from for PH-ILD. Now that they cannot detail for their product anymore, do you think that a lot of that new patient growth can come to TYVASO? Can that happen?
We do. I mean, if you think about the guardrails under the settlement agreement that were put in place in terms of Liquidia having to inform physicians to move patients over, to have a physician have to attest to the patient being a PAH patient if they're prescribing their therapy. So the guardrails put in place should naturally, over time, have those new PH-ILD patients move over to our therapy going forward. I think what you've seen maybe historically is now there were two sales teams talking about a therapy in PH-ILD, so there was increased awareness on it, just in general. I think over time, that will port over to UT based upon those dynamics and the guardrails and the settlement agreement.
Yeah
that rightfully supported kind of the intellectual property and what should be on a going-forward basis.
Great. Wonderful. I think one of the things that people are starting to look at again, sort of like a refresher, is what is the patient referral pattern for PAH versus PH-ILD? If you can just give us some background on that, because I think if the competitor is not going to look at PH-ILD, all these ILD specialist docs that would have been a focus of detailing effort for them, that would not be a focus anymore, and that in a way opens up the market opportunity for Tyvaso in PH-ILD. If you can talk about just like PH-ILD, what is the physician referral pattern to get the patients?
Yeah, well, to one of the points that you just made, it's a good thing that we just expanded our sales force in July, so we have more feet on the street that are able to detail these doctors about the benefits of Tyvaso in the PH-ILD patient population. Again, we should have the full benefit of that market now, where physician awareness has been growing, the education has been growing, we've been making push to diagnose patients. So we're really excited about the opportunity.
That's great. Awesome. Let's talk about IPF launch. I mean, that is a big milestone that a lot of investors are looking out for. Just if you can talk about, what are the efforts that you have under play? How do you think this market would start to open up for TYVASO?
Yeah. Thanks, Ash. It's a great question and one we're excited about. Just as a reminder, maybe for those not familiar with this story, the FDA's PDUFA date for the use of TYVASO in IPF is April 26th. In advance of that, we've talked about the commercial teams being expanded, and Michael has brought those in. On the other side, what we're doing is we're making sure that at time of launch, we have sufficient nebulizers to support a minimum 10,000 patients in the IPF space. We want to make sure as we approach that launch opportunity that we are ready to serve and support what we think is going to be a very attractive and large market. We're doing that by having nebulizers and starter kits available for those patients.
As you know, the clinical results for the TETON-1 and TETON-2 trial were very positive, and the best in any clinical trial in IPF to date. What we anticipate is significant and quick uptake in that disease state. Some folks had looked at JASCAYD as kind of a comparator qualitatively, and that's a good kind of one to model, although theirs is a pill, theirs was both IPF and PPF, so it could be a little bit different. Again, this is a space that has had few therapies, new therapies in the market. Coming to market with very powerful clinical trial results, we think it'll be pretty well received, and we expect a pretty quick and large uptake.
Yeah. That's exciting. I'm really looking forward to that. I guess the way that we think about it, being a nebulizer versus an oral therapy that just recently came to the market, can you talk about these patients? Is that a barrier at all for them if it's a different format of how the drug is being delivered, or is it ultimately about the data, that the data looks so good that there would be a very strong demand for it?
Sure. To your point, JASCAYD currently is a pill, and we're bringing a nebulizer to market. But the clinical results from our perspective were so positive and overwhelming that we think physicians and patients would want to be on nebulized TYVASO for IPF. Again, the clinical trials were very powerful.
Yeah.
Again, these are patients that ultimately, well, this market could actually be one that has dual therapy in itself anyway, so there could be polytherapy in this market. But overall, the results and the enthusiasm that we have seen and heard about, the results should be pretty positive to both patients, physicians, and frankly, to keep patients on therapy for a pretty long duration is what we anticipate.
Great. Awesome. When we get to the launch, I know you don't necessarily break down the PH versus PH-ILD revenue for TYVASO right now. Is there an intention that you would provide some more detailed metrics when we launch IPF, or is that going to be-
Yeah, I think to be determined, Ash. I think to be determined on what's really the best way for us to communicate thoughtfully kind of the uptake there in that space.
Yeah.
If you recall, we have done a few things historically in the PH-ILD space where we looked at patient adds, et cetera. I think more to come when Michael frames up the opportunity and how to think about communicating the uptake in that space.
Got it. Okay, that is great. I mean, look, like how you said that the data speaks for itself. A lot of physicians that we talk to are excited about looking at including TYVASO in their IPF treatment paradigm. I think one of the things investors have been focusing on is the discontinuation rate that we saw in the TETON study. I know, in general, there has been high discontinuation rate for ESBRIET and OFEV, and they still turned out to be multi-billion dollar franchises. Just like the way that you think about it, the discontinuation, what we saw in TETON, what is your expectation on what it would be in the real-world setting?
Yeah, absolutely. Look, ultimately, time will tell from a real-world setting. When you think about, as you just noted, the first-gen antifibrotics, and even JASCAYD included when you look at the registrational data, discontinuations are high, and the tolerability and safety profile of TYVASO is a lot different in the sense that you are not dealing with some of those really nasty GI-related side effects, not to mention having a quality of life benefit that was seen in the study. The profile of that in the real world could look different from a discontinuation point, especially relative to a clinical trial where it is difficult to extrapolate to a real-world setting, what you saw in the trial versus what could take place.
Got it. Great. Okay. If I talk about some of the other pipeline opportunities that you have. For the SMI, yeah, I think this is something that you talked about at the earnings that now expecting a 2027 approval. Was the thing previously you said the year end. Not a big change in the timeline, but just trying to understand, like, what are the additional inputs that you need to provide to the FDA?
Yeah, just to note
It will be a 2027 filing, whereas before we had communicated end of year 2026.
Right.
The reason we are not going to hit that is we need more time based upon a recent meeting with the FDA. We just determined that there is just additional work needed on the CMC and PK side. Nothing new in totality, and no expectations for patient outcomes-based data. Again, it is just more CMC/PK-related work that unfortunately will push the timing of the filing into next year.
Got it. Okay. On ralinepag, if you could just frame the launch opportunity for that would be super helpful.
Yeah. Just to remind folks, ralinepag was a clinical trial we unblinded earlier this year called ADVANCE OUTCOMES, and it would be a once-a-day oral prostacyclin. We are very enthusiastic about it, just in terms of this first oral therapy that is an NDA with the FDA that has an approval PDUFA date of end of June 2027. We think this will be very well received. We think it will be used right behind upfront therapy. From the clinicians that were involved in the clinical trial, some of the feedback was that they do not see a reason why every PAH patient would not be prescribed this. There is enthusiasm that may be different from the Wall Street perspective or the investor perspective, but in the clinical setting and the prescriber community, the feedback that we heard was very positive.
We think there will be a large opportunity for ralinepag in the PAH space. As you know, we have other development opportunities beyond that. This initial oral therapy for ralinepag that we anticipate calling Genraldi will be something that will be very well received.
Yeah. That is great. Then on the regulatory side here, the CMO that you are using, I know you talked about this at the earnings call that they had an OAI, which they have responded back to the FDA.
Yeah.
Do you feel confident that the timeline of the approval is still intact? Is there any contingency plan that you have if that regulatory issue could not be resolved?
Sure. It's a good question. We are aware that Sinopharm is communicating with the FDA, which is a very positive sign to resolve some of these FDA findings. We still do see there's a path, if everything works right, to achieve and be ready for that PDUFA date. But in the background, it's a very high priority for us. In the background, we're also looking at additional manufacturers should we need to supplement to be able to stay on track, which is a tall order, but the teams are very focused on it. I think the positive feedback is there is communication. They're working on it, Sinopharm that is. We're supporting them as best we can, but we're also looking in the background to try and find other means and methods to be able to support what the FDA has identified.
Great. Perfect. Then maybe switching gears to xenotransplantation.
Sure.
It's my favorite topic. Yeah, I guess you have those four patients, I believe, planning to dose the six by the end of the year.
Yeah.
The remaining two, I mean. Yeah, just if you can talk a little bit about, yeah, like is that on plan? When do we start to see some data percolating through?
Sure. As you just said, the expectation is to have the sixth patient from the first cohort, which is the last patient in the first cohort, transplanted by the end of this year. The way the design is set up is, 12 weeks after that transplant occurs, we will meet with the FDA and determine if we can move forward into the second cohort, which would be registration enabling to support a BLA, and it is up to 44 additional patients in that cohort. We could potentially see an outcome where the actual size of that cohort is sized down, just based on some conversations and what we are seeing in the space from some other competitors there.
Okay.
It is interesting, Ash, you asked about highlights, you know, at the beginning, and there is so much going on at UT. This is a big part of the story. It is a little bit further out, but as Harry outlined, between advancing these clinical trials, and there are three right now, there are two for the kidney and one for the heart in process, and you are seeing us scale some of the facilities. We have had some openings of some commercial facilities, both in Minnesota and Texas. So, in the background of all these other pipeline development activities in the IPF/PPF space, the xeno activity is certainly moving along quite nicely as well.
Yeah. That is great. I wanted to just ask if there is any question in the audience, and then maybe we can take one last one. All right. If there is no one, then yeah, I mean, I wanted to ask about the capital allocation. So I was actually going back and taking a look at what has been your cash position versus how much share repo that you have done. If you look at, like, three years ago, you had almost $5.5 billion of cash, and more recently, still strong cash and strong free cash flow generation for you. But there has been a fair bit of commitment to share repurchase, particularly in the last one or two years. So I am just curious, like, you know, following the story for a while, like, what is really driving this now? It seems like a little bit more urgency to deploy that.
When you think about just additional uses of cash, would share repurchase still be a focus as a top priority, or does that start to change a little bit?
It's a great question, and we've gotten it a lot based upon what you described, Ash, as your observations historically. Our capital allocation waterfall is still the same, which is we're going to invest internally in ourselves. We'll look at corporate development or business development, and third in that waterfall is share repurchase. What we've been able to demonstrate and put our money where our mouth is over these last few years is we have so much conviction in where we're going with all these clinical programs, really on the near term, that we felt that there's no better investment after we've satisfied our operating needs than to invest in ourselves. As you may be aware, we have currently a share repurchase program in place that will end in this fourth quarter, and the board recently just authorized another $2 billion.
At the same time, we used some capital for this royalty buydown. With the conviction in the business, the free cash flow generation, we feel that we ourselves are a great investment right now. If you look historically, we've been able to find those opportunities and time those, we think, very well. As where we are now, we're going to continue to do that in the near term. I think when you get out a few years out, if the business ramps as we expect with these opportunities in PAH, PH-ILD, and IPF, there will be a sizable cash generation as well, and we'll have to think about what the next opportunity is, whether it's corporate development or continuing share repurchase beyond just investing in ourselves.
Yeah. Great. Awesome. With that, we are out of time, so thank you so much.
Thank you very much, Ash. We appreciate it.